Back to Journals » Vascular Health and Risk Management » Volume 8

Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance

Authors Utsunomiya K

Received 28 March 2012

Accepted for publication 23 May 2012

Published 4 July 2012 Volume 2012:8 Pages 429—436


Review by Single-blind

Peer reviewer comments 2

Kazunori Utsunomiya

Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Tokyo, Japan

Abstract: This paper provides an update on the mechanisms of vascular impairment associated with insulin resistance and the pathogenesis of diabetic nephropathy and peripheral artery disease (PAD). It also considers the optimal treatment strategies for systemic vascular protection in light of recent findings. This area is of major clinical importance given the ongoing global epidemic of type 2 diabetes and the pivotal role played by insulin resistance in the mechanism of vascular impairment that manifests as macroangiopathy and microangiopathy. Timely diagnosis and intervention is critical in patients with systemic arteriosclerotic disease. Therefore, treatment strategies are aimed not only at targeting the presenting pathology, but also at reducing the risk of cardiovascular events. These efforts can help reduce the risk of both cardiovascular events and mortality. Treatment for PAD includes pharmacotherapy, endovascular treatment, and vascular reconstruction, along with exercise therapy. Because PAD can cause ischemia in the lower extremities, typical drug approaches include use of vasodilators and antiplatelet agents. Beraprost sodium and cilostazol are common choices in Japan, and their risks and benefits are discussed. Of note, beraprost has several therapeutic properties, including vascular endothelial protection, and antiplatelet and anti-inflammatory effects, in addition to vasodilatory activity. In patients with PAD, these activities improve the pathological process in the lower extremities and reduce the incidence of systemic vascular events. Recent preclinical findings indicate that beraprost improves not only ischemic extremities through its vasodilatory properties, but also reduces the insulin resistance which affects vascular endothelium. In this way, beraprost may contribute to an overall systemic vascular protective action. The use of agents, such as beraprost, which are capable of improving insulin resistance and resulting vascular endothelial function at an earlier disease stage, may ultimately contribute to increasing the life expectancy of patients with PAD.

Keywords: peripheral artery disease, insulin resistance, beraprost, vascular, protection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery

Kuroda Y, Hirayama C, Hotoda H, Nishikawa Y, Nishiwaki A

Vascular Health and Risk Management 2013, 9:593-598

Published Date: 7 October 2013

Perceptions of barriers to cardiac rehabilitation use in Brazil

Ghisi GLM, Santos RZ, Aranha EE, Nunes AD, Oh P, Benetti M, Grace SL

Vascular Health and Risk Management 2013, 9:485-491

Published Date: 30 August 2013

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion

Lichtenberg M, Käunicke M, Hailer B

Vascular Health and Risk Management 2012, 8:283-289

Published Date: 4 May 2012

Mixed dyslipidemias in primary care patients in France

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E

Vascular Health and Risk Management 2012, 8:247-254

Published Date: 19 April 2012

Absorbable stent: focus on clinical applications and benefits

Gonzalo N, Macaya C

Vascular Health and Risk Management 2012, 8:125-132

Published Date: 29 February 2012

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010